Study finds cutaneous squamous cell carcinoma test could save US Medicare almost $1bn

[cafead]

via Texas-based company Castle Biosciences has published results of a study investigating its DecisionDx cutaneous squamous cell carcinoma (SCC) test designed to guide patient selection for adjuvant radiation therapy (ART), which could save the US Medicare service $972 million annually.

article source